Metabolon Finds New Approach To Identify Risk For Premature Labor
The study, carried out in collaboration with co-authors Dr Roberto Romero and colleagues of the NICHD, NIH, and DHHS, aimed to identify prognostic and diagnostic biomarkers of preterm
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.